论文部分内容阅读
目的探讨补体激活产物C4d在非小细胞肺癌(NSCLC)组织中的表达及其与浸润、转移和预后的关系。方法采用酶联免疫吸附剂检测30例非小细胞肺癌患者血清中补体激活产物C4d的水平,并检测同期收治的30例肺良性病变患者血清中补体激活产物C4d水平。比较非小细胞肺癌患者血清中补体激活产物C4d与预后的关系。结果非小细胞肺癌患者中,补体激活产物C4d表达阳性的患者数量为18例,对照组中表达阳性的患者数量为4例,2组差异有统计学意义(P<0.05)。肺癌组患者术前补体激活产物C4d浓度均值为12.6 U/L,对照组患者补体激活产物C4d浓度均值为2.1 U/L,2组差异有统计学意义(P<0.05)。肺癌患者术前补体激活产物C4d浓度均值为12.6 U/L,术后补体激活产物C4d浓度均值为4.5 U/L,差异有统计学意义(P<0.05)。短期存活组(生存期小于1年)患者补体激活产物C4d浓度均值为7.3 U/L,长期存活组(生存期长于1年)患者补体激活产物C4d浓度均值为18.4 U/L,2组差异有统计学意义(P<0.05)。结论补体激活产物C4d在非小细胞肺癌患者和非良性疾病患者中表达差异显著,其生物学浓度与非小细胞肺癌患者的预后有直接联系,具有一定的临床推广意义,能作为肺癌患者早期诊断和预后预测的生物标志物。
Objective To investigate the expression of complement activation product C4d in non-small cell lung cancer (NSCLC) and its relationship with infiltration, metastasis and prognosis. Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the level of C4d in the serum of patients with non-small cell lung cancer (NSCLC). The level of C4d in the serum of 30 patients with benign lung disease was detected. To compare the relationship between C4d in serum and prognosis of patients with non-small cell lung cancer. Results In non-small cell lung cancer patients, the number of patients with positive expression of C4d was 18 cases. The number of patients with positive expression of C4d in control group was 4 cases. There was significant difference between the two groups (P <0.05). The average level of C4d concentration in patients with lung cancer was 12.6 U / L, while that in the control group was 2.1 U / L. The difference between the two groups was statistically significant (P <0.05). The mean C4d concentration of preoperative complement activation product in patients with lung cancer was 12.6 U / L, and the average value of postoperative C4d concentration was 4.5 U / L. The difference was statistically significant (P <0.05). The average level of C4d in short-term survivors (survival less than 1 year) was 7.3 U / L in patients with long-term survivors (survival longer than 1 year), and the mean level of C4d in patients with long-term survival was 18.4 U / L Statistical significance (P <0.05). Conclusions C4d expression is significantly different between non-small cell lung cancer patients and non-benign disease patients. The biological concentration of C4d is directly related to the prognosis of patients with non-small cell lung cancer and has certain clinical significance. It can be used as an early diagnosis for patients with lung cancer And prognostic biomarkers.